Compare CRDF & DIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRDF | DIT |
|---|---|---|
| Founded | 1999 | 1981 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Food Distributors |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.1M | 64.4M |
| IPO Year | 2012 | 1996 |
| Metric | CRDF | DIT |
|---|---|---|
| Price | $0.87 | $58.99 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $5.14 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 668.0 |
| Earning Date | 11-12-2026 | 11-09-2026 |
| Dividend Yield | N/A | ★ 1.14% |
| EPS Growth | 27.37 | ★ 173.91 |
| EPS | N/A | ★ 2.52 |
| Revenue | $365,993.00 | ★ $1,392,388,157.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $23.41 |
| Revenue Growth | ★ 49.61 | 5.30 |
| 52 Week Low | $0.71 | $58.62 |
| 52 Week High | $3.31 | $118.50 |
| Indicator | CRDF | DIT |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 39.92 |
| Support Level | N/A | N/A |
| Resistance Level | N/A | $70.51 |
| Average True Range (ATR) | 0.00 | 1.37 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 0.00 | 5.76 |
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.
Amcon Distributing Co is engaged in the wholesale and retail distribution of consumer products such as cigarettes, tobacco, confectionery, health food, and others. It operates in two segments: Wholesale distribution segment distributing consumer products to the retail outlets including convenience stores, grocery stores, liquor stores, drug stores and tobacco shops in the Central, Rocky Mountain, and Southern regions of the United States; and the Retail health food segment is a specialty retailer of natural/organic groceries and dietary supplements throughout the Midwest and Florida. The company earns a majority of the revenue from the Wholesale distribution segment.